Description
The JC159 monoclonal antibody specifically binds to CD235a which is encoded by GYPA [glycophorin A (MNS blood group)] and known as Sialoglycoprotein alpha or MN sialoglycoprotein. This heavily glycosylated type I transmembrane protein forms a ~36 kDa homodimer that bears the blood group M and N antigens in its N-terminal extracellular region. The JC159 antibody reacts with CD235a (Glycophorin A) but does not crossreact with the homologous CD235b (Glycophorin B) molecule. In contrast, the GA-R2 (HIR2) antibody more broadly recognizes both Glycophorins A and B, ie, is specific for CD235ab (Glycophorin A/B). CD235a (Glycophorin A) is expressed on human erythrocytes, erythroid precursor cells and certain leukemic cell types. This highly expressed, negatively charged surface sialoglycoprotein contributes to the negative charge of the red cell membrane that may help prevent erythrocyte aggregation in the circulation. This glycophorin provides structural stability to the erythrocyte membrane by associating with other cell surface proteins such as the anion exchanger, SLC4A1 (Band 3). SLC4A1 mediates gas exchange—oxygen uptake and carbon dioxide release—across the erythrocyte membrane. CD235a (Glycophorin A) binds to multiple ligands including Siglec-5 (CD170) which may help mediate interactions between erythrocytes and immune cells, eg, during inflammation, immune surveillance, or removal of damaged or aged red blood cells. The malaria parasite Plasmodium falciparum binds to CD235a (Glycophorin A) by its surface Erythrocyte Binding Antigen 175 (EBA-175) which can promote parasite entry and infection of erythrocytes. Viruses including influenza A and B viruses, hepatitis A virus, Sendai virus, encephalomyocarditis virus (EMCV), and reoviruses similarly bind to this glycophorin which can facilitate viral infection of cells.
Bead-based compensation or unmixing controls, such as BD® CompBeads or BD™ SpectraComp™, can be used as surrogates to assess fluorescence spillover when bound to fluorochrome-conjugated antibodies. Although these beads have spectral properties similar to cells, variations in spectral emission may occur, resulting in differing spillover values compared to biological controls. Therefore, it is considered best practice to compare the spillover obtained from cells and bead-based controls when using BD® CompBeads or BD™ SpectraComp™ for the first time, to ensure they are appropriate for the intended application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
11. Alexa Fluor™ is a trademark of Life Technologies Corporation.
12. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
